I think MIT's breakthrough is a huge step forward, but it also highlights just how tricky drug delivery still is. Scaling up nanoparticle production is essential if we ever want these treatments to be more than just a cool lab experiment. But even with this progress, we’re still stuck with the same old problem—getting drugs exactly where they need to go without wrecking the rest of the body.
That’s why I find DNA nanobots fascinating, even if they still feel a little like science fiction. Instead of just improving how we make nanoparticles, DNA nanobots could take targeting to another level—programming them to only release drugs when they hit specific cancer markers. The idea of a ‘smart drug courier’ that doesn’t dump toxins everywhere is really appealing. Will it actually work in humans at scale? Who knows. But five years ago, I wouldn’t have expected MIT to make mass nanoparticle production look feasible either.
That’s why I find DNA nanobots fascinating, even if they still feel a little like science fiction. Instead of just improving how we make nanoparticles, DNA nanobots could take targeting to another level—programming them to only release drugs when they hit specific cancer markers. The idea of a ‘smart drug courier’ that doesn’t dump toxins everywhere is really appealing. Will it actually work in humans at scale? Who knows. But five years ago, I wouldn’t have expected MIT to make mass nanoparticle production look feasible either.
If you’re curious about the DNA nanobot approach: https://dnananobots.com/antibody-drug-conjugates/